

Health Survey (SF-36) was also administered. Fatigue ratings were correlated with measures of depression severity (BDI and 17-item Hamilton Depression Rating Scale, HDRS17), anxiety (State/ Trait Anxiety Inventory, STAI) and somatization (the somatization subscale of the Symptom Checklist 90-Revised, SCL90-R).

Results: Fatigue severity, as measured with FQ and VAS correlated positively to a significant degree with state anxiety ($r=0.276$, $p=0.04$ and $r=0.356$, $p=0.007$, respectively) while vitality correlated negatively with trait anxiety ($r=-0.312$, $p=0.02$). Correlations remained significant after depression severity was controlled for. All fatigue and vitality measures correlated strongly with somatisation scores, even after controlling for depression severity, state or trait anxiety.

Conclusions: The preliminary results of this ongoing study indicate that the severity of fatigue in major depression correlates with state / trait anxiety and somatisation.

P028

Long-term treatment of severe major depression (MDD) with escitalopram or paroxetine

J.P. Boulenger¹, A.K.T. Huusom², E. Weiller², I. Florea².
¹ *University Department of Adult Psychiatry, CHU de Montpellier and INSERM E361, Montpellier, France* ² *H.Lundbeck A/S, Copenhagen, Denmark*

Purpose: This randomised, double-blind fixed-dose study compared the efficacy of escitalopram and paroxetine in the long-term treatment of patients with severe MDD.

Methods: Patients with DSM-IV-defined MDD and baseline Montgomery-Åsberg Depression Rating Scale (MADRS ≥ 30) were randomised in a 1:1 ratio to 24 weeks of double-blind treatment with either escitalopram (20mg) or paroxetine (40mg). The primary analysis of efficacy was an analysis of covariance of change from baseline to Week 24 in MADRS total score using the last observation carried forward (LOCF) method.

Results: At endpoint (24 weeks), the mean change from baseline in total MADRS score was -25.2 for escitalopram-treated patients ($n=228$) and -23.1 for paroxetine-treated patients ($n=223$), a difference of 2.1 points ($p<0.05$). The difference on the MADRS (LOCF) was significantly in favour of escitalopram from Week 8 onwards. Response rates ($\geq 50\%$ decrease in MADRS) after 24 weeks were 82% (escitalopram) and 77% (paroxetine). Remission rates (MADRS ≤ 12) were 75% (escitalopram) and 67% (paroxetine) ($p<0.05$). These results were supported by a significantly greater difference in favour of escitalopram on all secondary efficacy analyses. For very severely depressed patients (baseline MADRS ≥ 35), there was a difference of 3.5 points in favour of escitalopram ($p<0.05$) at endpoint (24 weeks). The overall withdrawal rate for patients treated with escitalopram (19%) was significantly lower than with paroxetine (32%) ($p<0.01$). The withdrawal rate due to AEs was significantly lower for escitalopram (8%) compared to paroxetine (16%) ($p<0.05$).

Conclusion: Escitalopram was significantly more effective than paroxetine in the treatment of patients with severe MDD.

P029

Meta analysis of randomised controlled trials describing the effectiveness of venlafaxine in the treatment of major depressive disorder

N. Freemantle, P. Tharmanathan. *Department of Primary Care, University of Birmingham, Birmingham, United Kingdom*

Background: A number of different antidepressant types are available, and many randomised trials (most modest in size and statistical power) have evaluated their relative effectiveness. Venlafaxine is a well established antidepressant, and previous work has indicated that it may be superior to SSRIs in treating depression.

Methods: We conducted a meta analysis of all available trials comparing venlafaxine and SSRIs examining the outcomes of response, remission and relative tolerability. Trials were identified through searches of Medline, Embase, Cochrane Library and through accessing unpublished trials held by the manufacturer. Results based on intention to treat analyses, were pooled using theoretically exact conditional maximum likelihood methods for fixed effects, and numerical simulation for full random effects.

Results: We identified 34 trials comparing venlafaxine with an SSRI, including 6374 patients. Venlafaxine was compared with fluoxetine in 18 trials, with paroxetine in 6 trials and with sertraline in 4 trials. Other comparators were citalopram (2 trials), escitalopram (2 trials) and fluvoxamine (2 trials). Response to venlafaxine was superior to that of alternative SSRIs, odds ratio 1.17 (95% CI 1.05 to 1.30; $P = 0.0052$). Similarly, for remission, venlafaxine was superior to SSRIs, odds ratio 1.24 (95% CI 1.10 to 1.40; $P = 0.0004$). Similar results were identified for full random effects analyses. Overall drop out was similar for SSRIs and venlafaxine.

Conclusion: Venlafaxine is more effective than SSRIs in achieving response and remission, and appears similarly tolerated.

P030

Alexithymia and winter seasonal affective disorder: Prevalence, sociodemographic and clinical correlates

S. Friedman, M. Oumaya, C. Even, J. Thuile, J.D. Guelfi, F. Rouillon. *CMME, CH Sainte-Anne, Université Paris, Paris, France*

Background: Alexithymia refers to a cluster of cognitive-affective deficit in emotion-processing characterized by difficulties in experiencing and expression emotions. Seasonal Affective Disorder (SAD) is a form of recurrent depressive or bipolar disorder highlighting somatic symptoms (hyperphagia and snacking for carbohydrate/high fat food, hypersomnia). Alexithymic characteristics could explain why some patients suffering from winter depression are likely to selectively focus on somatic symptoms.

Aims: We report the first study assessing the prevalence, sociodemographic and clinical correlates of Alexithymia in patients suffering from Winter Seasonal Affective Disorder (SAD).

Methods: In a sample of 59 consecutive depressed outpatients with winter seasonal features (DSM-IV criteria), alexithymia was assessed with the Toronto Alexithymia Scale -20 (TAS-20), severity of depression was assessed with the Hamilton Depression Rating Scale and Sigh-SAD version -25, depressive and anxious symptoms were evaluated with the depression and anxiety subscales of the Hospital Depression scale (HAD).

Results: The prevalence of alexithymia was 35.6%. Total TAS-20 scores were significantly correlated with: age ($r= 0.27$), duration of the illness ($r= 0.31$), depression and anxiety HAD scores, respectively $r = 0.34$ and $r= 0.37$. Alexithymia was not related to other sociodemographic and clinical variables (hyperphagia, snacking for carbohydrate food and hypersomnia).

Conclusions: Alexithymia is frequent in patients suffering from Winter Seasonal Affective Disorder. Nevertheless, this study does not provide support to a relationship between alexithymia and